Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C patients: Effectiveness prediction by gene analysis and efficacy with Fluvastatin combination

Trial Profile

Peg-IFN-alfa-2b/Ribavirin combination therapy for chronic hepatitis C patients: Effectiveness prediction by gene analysis and efficacy with Fluvastatin combination

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2016

At a glance

  • Drugs Fluvastatin (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 21 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top